Dr. Matthew Gubens is a board-certified medical oncologist based in San Francisco, California. He graduated from the Stanford University School of Medicine and did his residency in internal medicine at the UCSF. He also did a fellowship in medical oncology at the Stanford University. He is specialized in the treatment of cancer affecting the larynx, lungs, and mesothelioma. With about two decades of clinical experience, Dr. Gubens is affiliated with the UCSF Medical Center and has also contributed to several research publications.
American Board of Internal Medicine - Oncology
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
Sanlorenzo, M.,Vujic, I.,Daud, A.,Algazi, A.,Gubens, M.,Luna, S. A.,Lin, K.,Quaglino, P.,Rappersberger, K.,Ortiz-Urda, S.; JAMA Dermatol. 2015 Jul 30.See more >>
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors.
Smith, D. C.,Eisenberg, P. D.,Manikhas, G.,Chugh, R.,Gubens, M. A.,Stagg, R. J.,Kapoun, A. M.,Xu, L.,Dupont, J.,Sikic, B.; Clin. Cancer Res.. 2014 Oct 18.See more >>
Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
Woodard, G. A.,Gubens, M. A.,Jahan, T. M.,Jones, K. D.,Kukreja, J.,Theodore, P. R.,Cardozo, S.,Jew, G.,Clary-Macy, C.,Jablons, D. M.,Mann, M. J.; Clin Lung Cancer. 2014 Sep 27.See more >>